文献速递白血病

索拉非尼或安慰剂治疗新诊断急性髓系白血病:随机对照SORAML试验长期随访

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
PubMed 文献 · Leukemia · 2021-02-18

SORAML随机安慰剂对照试验长期随访(中位78个月)显示,新诊断的≤60岁适合强化疗的AML患者,在标准化疗及维持治疗基础上加用索拉非尼,5年无事件生存率(EFS)显著改善(41% vs 27%,HR 0.68,p=0.011),5年无复发生存率(RFS)亦显著改善(53% vs 36%,HR 0.64,p=0.035)。尽管5年总生存率(OS)未达统计学显著差异(61% vs 53%,HR 0.82,p=0.282),结果仍证实索拉非尼具有抗白血病活性。

要点

  • 索拉非尼联合化疗显著改善5年EFS(41% vs 27%)和RFS(53% vs 36%)。
  • 5年OS在索拉非尼组与安慰剂组分别为61%和53%,差异无统计学意义。
  • 复发患者中88%接受了异基因造血干细胞移植,移植后4年复发累积发生率54% vs 35%,OS 32% vs 50%。

核心结论

  • 在标准化疗及维持治疗基础上加用索拉非尼可显著延长新诊断AML患者的EFS和RFS,尽管OS获益未达统计学显著性。

研究设计与样本

  • 随机安慰剂对照SORAML试验长期随访研究,中位随访78个月,纳入≤60岁新诊断适合强化疗的AML患者,索拉非尼组134例,安慰剂组133例。

主要发现

  • 5年EFS为41% vs 27%(HR 0.68;p=0.011),5年RFS为53% vs 36%(HR 0.64;p=0.035)。
  • 所有患者从随机化起5年OS为61% vs 53%(HR 0.82;p=0.282)。
  • 复发患者中88%接受了异基因造血干细胞移植,挽救性移植后4年复发累积发生率为54% vs 35%,OS为32% vs 50%。

关键数值与推荐

  • 5年EFS:索拉非尼组41% vs 安慰剂组27%(HR 0.68;p=0.011)。
  • 5年RFS:索拉非尼组53% vs 安慰剂组36%(HR 0.64;p=0.035)。
  • 5年OS:索拉非尼组61% vs 安慰剂组53%(HR 0.82;p=0.282)。
  • 挽救性allo SCT后4年复发累积发生率:54% vs 35%;OS:32% vs 50%。

临床怎么用

  • 对于≤60岁新诊断适合强化疗的AML患者,可考虑在化疗及维持治疗中加用索拉非尼以改善EFS和RFS。

局限性

  • OS获益未达统计学显著性,长期随访中部分患者接受异基因移植等后续治疗可能影响生存分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement in event-free (EFS) and relapse-free survival (RFS). In order to describe second-line treatments and their implications on overall survival (OS), we performed a study after a median follow-up time of 78 months. Newly diagnosed fit AML patients aged ≤60 years received sorafenib (n = 134) or placebo (n = 133) in addition to standard chemotherapy and as maintenance treatment. The 5-year EFS was 41 versus 27% (HR 0.68; p = 0.011) and 5-year RFS was 53 versus 36% (HR 0.64; p = 0.035). Allogeneic stem cell transplantation (allo SCT) was performed in 88% of the relapsed patients. Four years after salvage allo SCT, the cumulative incidence of relapse was 54 versus 35%, and OS was 32 versus 50%. The 5-year OS from randomization in all study patients was 61 versus 53% (HR 0.82; p = 0.282). In conclusion, the addition of sorafenib to chemotherapy led to a significant prolongation of EFS and RFS. Although the OS benefit did not reach statistical significance, these results confirm the antileukaemic activity of sorafenib.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Röllig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021. PMID: 33603142. doi:10.1038/s41375-021-01148-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。